Sage Therapeutics, Inc. (NASDAQ:SAGE) insider Albert Robichaud sold 60,000 shares of the stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $159.43, for a total value of $9,565,800.00. Following the completion of the sale, the insider now owns 152,759 shares of the company’s stock, valued at approximately $24,354,367.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Sage Therapeutics, Inc. (NASDAQ SAGE) traded down $6.62 during trading hours on Thursday, reaching $158.03. The company’s stock had a trading volume of 873,174 shares, compared to its average volume of 605,605. Sage Therapeutics, Inc. has a 52 week low of $44.55 and a 52 week high of $173.36.
Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.98) by $0.01. The firm’s revenue for the quarter was up .0% on a year-over-year basis. sell-side analysts expect that Sage Therapeutics, Inc. will post -7.4 earnings per share for the current year.
A number of research analysts recently commented on the company. Canaccord Genuity reduced their price target on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating for the company in a report on Tuesday, September 12th. Needham & Company LLC reduced their price target on Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, September 13th. BMO Capital Markets reissued an “outperform” rating and issued a $112.00 price target (up previously from $85.67) on shares of Sage Therapeutics in a report on Friday, November 17th. Cowen reduced their price target on Sage Therapeutics from $100.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, September 12th. Finally, Raymond James Financial increased their price target on Sage Therapeutics to $109.00 and gave the company a “buy” rating in a report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $171.21.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.